|

Coronavirus: Scientists hail 'groundbreaking' discovery of antibody which prevents infection – SKY

As scientists from around the world rush to find a cure for the coronavirus, picking up on an article by SKY News, there is news of research into antibodies which target the SARS coronavirus and scientists have identified one that blocks COVID-19.

"Scientists have discovered an antibody which prevents the coronavirus from infecting human cells in "groundbreaking research" which could lead to the development of new treatments," the article reads.

Lead paragraphs

Building on research into the SARS coronavirus, scientists from Utrecht University in the Netherlands, as well as the Erasmus Medical Centre and the company Harbour BioMed (HBM), have identified a potential method of neutralising COVID-19.

They discovered that an antibody which prevents the SARS virus from infecting human cells could also block the novel coronavirus from infecting human cells too, according a peer reviewed study published on Monday in the journal Nature Communications.

Testing their collection of antibodies on cultured human cells, researchers discovered one which binds to a specific part which is present in both SARS and the virus causing COVID-19.

Key notes

  • The discovery could offer an initial step towards developing a fully-human antibody to treat or prevent the disease.
  • The neutralising antibody "has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus," said Dr Berend-Jan Bosch, co-lead author on the study.
  • The discovery provided "a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment," –  said Dr Berend-Jan Bosch. "The antibody used in this work is 'fully human', allowing development to proceed more rapidly and reducing the potential for immune-related side effects," he added.
  • The fully-human antibody is different from conventional therapeutic antibodies, which are often first developed in other species before being "humanised" so they can be transmitted to people.
  • It was developed using Harbour BioMed's H2L2 transgenic mouse technology - effectively a mouse which has been genetically engineered to contain human genes, enabling researchers to develop "human" antibodies without testing them on living people.
  • "This is groundbreaking research," said Dr Jingsong Wang, the chief executive of HBM.

Market implications

This is undoubtedly good news and should help to put a foundation under markets. However, with trade wars back on the agenda, there is no escaping the prospects of a prolonged season of risk-off, volatility and uncertainty until, a) a cure is implemented, b) a vaccine is developed, c) China is proven innocent of the speculated accusations of the US following an investigation and d) global trade and the world economy can start to heal. 

Author

Ross J Burland

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

More from Ross J Burland
Share:

Editor's Picks

EUR/USD climbs to daily highs near 1.1820

EUR/USD now picks up pace and advances to the area of daily peaks north of the 1.1800 barrier at the end of the week. The pair’s decent move higher comes against the backdrop of a generalised lack of direction in the FX galaxy and the mild offered stance in the US Dollar.

GBP/USD trims losses, retests 1.3460

After briefly challenging its key 200-day SMA near 1.3440, GBP/USD now manages to regain some balance and revisit the 1.3460 zone on Friday. Cable’s pullback comes as the selling pressure on the Greenback gathers traction, reigniting some recovery in the risk-linked space.

Gold flirts with four-week highs past $5,200

Gold extends its rebound, climbing for a third consecutive session and pushing back above the $5,200 mark per troy ounce on Friday. The move higher continues to draw support from lingering geopolitical tensions and the ongoing uncertainty surrounding US trade policy, both of which are keeping safe-haven demand firmly in play.

Bitcoin, Ethereum and Ripple consolidate with short-term cautious bullish bias

Bitcoin, Ethereum and Ripple are consolidating near key technical areas on Friday, showing mild signs of stabilization after recent volatility. BTC holds above $67,000 despite mild losses so far this week, while ETH hovers around $2,000 after a rejection near its upper consolidation boundary. 

Changing the game: International implications of recent tariff developments

The Supreme Court ruling on International Emergency Economic Powers Act (IEEPA) tariffs provides limited relief for the rest of the world, with weighted average tariff rates modestly lower.

Starknet unveils strkBTC, shielded Bitcoin transactions on Ethereum Layer 2

Starknet, the Ethereum Layer 2 network developed by StarkWare, today announced strkBTC, a wrapped Bitcoin asset that introduces optional shielding while preserving full DeFi composability.